View Older Stories View More Recent Stories

Mar 16, 2022 01:30PM LYNPARZA® (olaparib) Reduced Risk of Death by 32% in Patients With Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer in Phase 3 OlympiA Trial
Mar 15, 2022 06:46AM Merck (MRK) to Evaluate KEYTRUDA in Combination with LYNPARZA in Patients with Metastatic Castration-Resistant Prostate Cancer to Stop for Futility
Mar 15, 2022 06:45AM Merck Announces KEYLYNK-010 Trial Evaluating KEYTRUDA® (pembrolizumab) in Combination with LYNPARZA® (olaparib) in Patients with Metastatic Castration-Resistant Prostate Cancer to Stop for Futility
Mar 11, 2022 07:51PM FDA Approves LYNPARZA® (olaparib) as Adjuvant Treatment for Patients With Germline BRCA-Mutated (gBRCAm), HER2-Negative High-Risk Early Breast Cancer Who Have Been Treated With Neoadjuvant or Adjuvan
Mar 7, 2022 06:46AM Merck's (MRK) KEYTRUDA Demonstrated Significant Improvement in DMFS Compared to Placebo as Adjuvant Therapy for Patients With Resected Stage IIB and IIC Melanoma in Phase 3 KEYNOTE-716 Trial
Mar 7, 2022 06:45AM Merck to Hold Investor Event to Highlight Growing Cardiovascular Portfolio and Pipeline
Mar 7, 2022 06:45AM Merck’s KEYTRUDA® (pembrolizumab) Demonstrated Significant Improvement in Distant Metastasis-Free Survival (DMFS) Compared to Placebo as Adjuvant Therapy for Patients With Resected Stage IIB and II
Mar 4, 2022 06:45AM Merck to Participate in Cowen’s 42nd Annual Health Care Conference
Mar 1, 2022 10:16AM Merck (MRK) Announces Retirement of Julie L. Gerberding
Mar 1, 2022 10:15AM Dr. Julie L. Gerberding to Retire from Merck
Feb 25, 2022 06:46AM Merck (MRK) KEYTRUDA Plus LENVIMA Approved in Japan for Radically Unresectable or Metastatic Renal Cell Carcinoma
Feb 25, 2022 06:45AM KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Approved in Japan for Radically Unresectable or Metastatic Renal Cell Carcinoma
Feb 23, 2022 08:40AM MilliporeSigma Announces Closing of Exelead Acquisition and Plans to Invest More Than € 500 Million in Technology Scale-Up
Feb 23, 2022 06:45AM Merck Shares Environmental, Social & Governance Priorities and Strategy
Feb 18, 2022 01:00PM European Commission Approves TEPMETKO® (tepotinib) for Patients with Advanced NSCLC with METex14 Skipping Alterations
Feb 16, 2022 06:45AM Merck (MRK) Appoints New Leadership for Human Health Business
Feb 16, 2022 06:45AM Merck Announces New Leadership for Human Health Business
Feb 14, 2022 05:04PM AstraZeneca (AZN) and Merck (MRK) Announce LYNPARZA plus Abiraterone Reduced Risk of Disease Progression by 34% vs. Standard-of-Care in 1st-Line Metastatic Castration-Resistant Prostate Cancer
Feb 14, 2022 05:00PM LYNPARZA® (olaparib) Plus Abiraterone Reduced Risk of Disease Progression or Death by 34% Versus Abiraterone in First-Line Metastatic Castration-Resistant Prostate Cancer, Regardless of Biomarker Sta
Feb 14, 2022 06:45AM Merck to Hold Event to Discuss Long-Term Environmental, Social & Governance Priorities
Feb 10, 2022 06:45AM Merck to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
Feb 9, 2022 05:00PM Merck (MRK) Announces Publication of Pivotal Phase 3 Data for KEYTRUDA in High-Risk Early-Stage Triple-Negative Breast Cancer
Feb 9, 2022 05:00PM Pivotal Phase 3 Data for KEYTRUDA® (pembrolizumab) in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC) Published in the New England Journal of Medicine
Feb 8, 2022 06:47AM Merck (MRK) and Ridgeback Supplied 3.1M Courses of Molnupiravir to the US
Feb 8, 2022 06:45AM Merck and Ridgeback Announce That 3.1 Million Courses of Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, Have Been Supplied to the U.S. Government for Use in the United States
Feb 7, 2022 09:05AM MilliporeSigma Announces Organizational Transformation to Strengthen CDMO Offering and Accelerate Future Growth
Feb 4, 2022 06:45AM Merck to Participate in the Guggenheim Oncology Conference 2022
Feb 3, 2022 06:30AM Merck Announces Fourth-Quarter and Full-Year 2021 Financial Results
Jan 28, 2022 06:47AM Merck (MRK) and Ridgeback Report Molnupiravir Demonstrated Activity Against Omicron Variant in In Vitro Studies
Jan 28, 2022 06:45AM Merck and Ridgeback’s Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, Demonstrated Activity Against Omicron Variant in In Vitro Studies
Jan 27, 2022 06:49AM Merck (MRK) Announce EC Approves KEYTRUDA as Adjuvant Therapy for Certain Patients With RCC Following Surgery
Jan 27, 2022 06:45AM European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery
Jan 25, 2022 01:34PM Merck Announces Second-Quarter 2022 Dividend
Jan 24, 2022 06:45AM Merck (MRK) Announces FDA Issues CRL for gefapixant
Jan 24, 2022 06:45AM Merck Provides U.S. and Japan Regulatory Update for Gefapixant
Jan 20, 2022 06:51AM Merck (MRK) Announces Publication of Results of Pivotal Phase 3 KEYNOTE-775/Study 309 Trial of KEYTRUDA
Jan 20, 2022 06:50AM Results From Pivotal Phase 3 KEYNOTE-775/Study 309 Trial of KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Advanced Endometrial Carcinoma Published in the New England Journal of Medicine
Jan 20, 2022 06:45AM Merck (MRK) Announces Frank Clyburn's Upcoming Resignation
Jan 20, 2022 06:45AM Frank Clyburn to Leave Merck
Jan 18, 2022 05:01PM Merck's (MRK) KEYTRUDA Significantly Improved OS Versus Placebo in Certain Patients With Advanced HCC Previously Treated With Sorafenib
Jan 18, 2022 05:00PM Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Versus Placebo in Certain Patients With Advanced Hepatocellular Carcinoma (HCC) Previously Treated With Sorafenib
Jan 18, 2022 08:02AM Merck Animal Health's Third Veterinarian Wellbeing Study Reveals Increased Health Challenges and Psychological Distress Among Veterinarians
Jan 18, 2022 06:45AM Merck (MRK), Ridgeback Announce Supply Agreement with UNICEF for Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine
Jan 18, 2022 06:45AM Merck and Ridgeback Announce Supply Agreement with UNICEF for Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine
Jan 10, 2022 08:31AM Gilead Sciences (GILD) Enters Clinical Collaboration with Merck (MRK) to Evaluate Trodelvy in Combination With KEYTRUDA
Jan 10, 2022 06:46AM Merck (MRK) Announces KEYTRUDA Showed Statistically Significant Improvement in Disease-Free Survival Versus Placebo as Adjuvant Treatment for Patients With Stage IB-IIIA Non-Small Cell Lung Cancer Reg
Jan 10, 2022 06:45AM Merck’s KEYTRUDA® (pembrolizumab) Showed Statistically Significant Improvement in Disease-Free Survival Versus Placebo as Adjuvant Treatment for Patients With Stage IB-IIIA Non-Small Cell Lung Canc
Jan 7, 2022 04:30PM Merck to Hold Fourth-Quarter and Full-Year 2021 Sales and Earnings Conference Call on February 3
Jan 7, 2022 05:52AM Absci Corporation (ABSI) Enters Research Collaboration with Merck (MRK)
Jan 5, 2022 06:30AM FDA Accepts Samsung Bioepis’ and Organon’s (OGN) sBLA for their Citrate-Free, High-Concentration HUMIRA® (Adalimumab) Biosimilar Candidate
View More Recent Stories View Older Stories